Upcoming Events Antibody Engineering & Therapeutics 2017

11th Dec 2017

Gut-Brain Axis Summit 2017

12th Dec 2017

10th Annual Biotech Showcase 2018

8th Jan 2018

7th Trial Master File Summit 2018

16th Jan 2018


22nd Jan 2018


E-newsletter - Latest Issue Of Pharma Affairs Newsletter
Latest on Pharma Industry


AstraZeneca to divest remaining anaesthetics portfolio rights

AstraZeneca will sell the remaining rights to its anaesthetic medicines portfolio to Aspen Pharmacare in a deal worth up to $766 million. Last year, the company sold rights to its global anaesthetics portfolio outside the US to Aspen under a $770-million agreement.....Read More...

FDA approves first cancer biosimilar

The US Food and Drug Administration has approved Amgen’s Mvasi (bevacizumab-awwb) as a biosimilar to Roche/Genentech’s Avastin (bevacizumab) for the treatment of multiple types of cancer, making it the first biosimilar approved in the country for the treatment of cancer. ... Read More...

Market Reports

Sickle Cell Market (SC) Global Analysis Industry Size, Share, Trends, Growth, Demand and Forecasts to 2030 - MarketReportsOnline

This latest report "Global Sickle Cell Market: Industry Analysis & Outlook (2020-2030)" provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S, and Europe along with the global market...Read More...

MiMedx Reports Exceptional Results in Phase 2B Clinical Trial on the Use of AmnioFix® Injectable in the Treatment of Plantar Fasciitis

MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that it has closed enrollment in the Company's Plantar Fasciitis Investigational ...Read More...

Press Releases

Mainstay Medical’s ReActiv8-B Clinical Trial Passes Mid-point Trial on target to complete enrolment around end 2017

Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable restorative neurostimulation system to treat disabling Chronic Low Back Pain (“CLBP”), announces that over half the required number of implants in the ReActiv8-B Clinical Trial have been performed... Read More...

Oxeia Biopharmaceuticals Announces Clinical Advancement Of Concussion Treatment

Oxeia Biopharmaceuticals Inc., announces its acquisition of rights to SUN11031, synthetic human ghrelin, from Kinemed Inc. Oxeia will develop SUN11031 as OXE-103 to treat concussions and other acute neurotrauma. "Ghrelin is a well-characterized molecule with pleiotropic neuroprotective properties that are applicable to concussions. With SUN11031 we are able to rapidly initiate Phase 2 clinical studies for concussion... Read More...